Catalent's SMARTag® ADC Pipeline and New Enhanced Conjugates Offering Featured at 16th World ADC San Diego

TAMPA, Fla.--(BUSINESS WIRE)--Catalent, Inc. presented new advancements in its SMARTag® antibody-drug conjugate (ADC) technology at the 16th World ADC San Diego conference.

Business Wire • Nov 4, 2025

Catalent Debuts New Corporate Brand, Elevating Customer Service Excellence by “Championing the Missions that Matter™”

TAMPA, Fla.--(BUSINESS WIRE)--Catalent, Inc., a leading global contract development and manufacturing organization, today unveiled its new corporate brand, marking a strategic evolution that underscores the company's commitment to delivering unparalleled customer service and its focus on “championing the missions that matter.” The new approach reflects Catalent's dedication to helping its pharmaceutical, biotech and consumer health customers bring their life-enhancing and life-changing solution.

Business Wire • Oct 28, 2025

Lisata Therapeutics CEO discusses Catalent deal - ICYMI

Lisata Therapeutics Inc (NASDAQ:LSTA) CEO Dr David Mazzo talked with Proactive about the company's new collaboration with Catalent, which reinforces its strategy to leverage the broad applicability of its lead molecule, certepetide, across multiple cancer types and treatment modalities. Proactive: Hello, you're watching Proactive.

Proactive Investors • Oct 11, 2025

Lisata Therapeutics inks global product license deal with Catalent

Lisata Therapeutics Inc (NASDAQ:LSTA) announced that it has entered into a global product license agreement with Catalent Inc, which would allow Catalent to incorporate Lisata's certepetide into antibody-drug conjugates (ADCs) developed using Catalent's SMARTag technology platform.  The clinical-stage pharmaceutical company said Certepetide, a proprietary, internalizing RGD (arginyl-glycyl-aspartic acid), or “iRGD” cyclic peptide, is being tested by Lisata as a cancer therapeutic to be used in combination with other anti-cancer agents to enhance tumor targeting and penetration and improve treatment outcomes.

Proactive Investors • Oct 8, 2025

Asia-Pacific Pharmaceutical CMO Market Share Analysis, Trends and Growth Forecasts to 2030 Featuring Catalent, Recipharm, Jubilant Life Sciences and More

Key industry drivers include cost advantages in China, 100% FDI in India, and demand for injectable drugs in cancer research Key industry drivers include cost advantages in China, 100% FDI in India, and demand for injectable drugs in cancer research

GlobeNewsWire • Jun 6, 2025

Prolific Machines Appoints Former Catalent Chief Scientific Officer to Board of Directors

EMERYVILLE, Calif.--(BUSINESS WIRE)--Prolific Machines announces appointment of Julien Meissonnier, former Chief Scientific Officer of Catalent, to its Board as an Independent Director.

Business Wire • May 15, 2025

Lisata Therapeutics talks ADC breakthrough with Catalent – ICYMI

Lisata Therapeutics Inc earlier this week discussed the potential of certepetide in antibody-drug conjugate (ADC) applications through a new collaboration with Catalent. The company told investors that it entered a research license agreement with Catalent to evaluate certepetide as a payload in SMARTag dual-payload ADCs.

Proactive Investors • Apr 19, 2025

Lisata Therapeutics signs research license with Catalent

Lisata Therapeutics Inc (NASDAQ:LSTA) announced that it has entered into a research license agreement with Catalent to evaluate certepetide, its iRGD cyclic peptide candidate, using Catalent's SMARTag antibody-drug conjugate (ADC) platform. The research will focus on preclinical testing for diseases such as advanced solid tumors.

Proactive Investors • Apr 15, 2025

Catalent Announces New Board Appointments

SOMERSET, N.J.--(BUSINESS WIRE)--Catalent, Inc., the leader in enabling the development and supply of better treatments for patients worldwide, today announced that it has appointed Susan Mahony, Marie-France Tschudin and Tim Walbert to its Board of Directors as the company continues its growth under Novo Holdings' ownership. Alessandro Maselli, President and CEO, and Board member of Catalent, said “I am excited to work closely with these new Board members as we drive continued growth as an ind.

Business Wire • Feb 20, 2025

Novo Holdings looks to double Catalent size with eye on Trump US manufacturing focus

Novo Holdings, the controlling shareholder of Novo Nordisk , hopes to double the size of its recently acquired contract drugmaker Catalent over five years, a senior partner at the investment firm said, as it prepares for a likely focus on U.S. manufacturing by President-elect Donald Trump.

Reuters • Jan 16, 2025